Immunocompromised patients with blood cancers face dramatically higher risks from common respiratory viruses that healthy individuals easily overcome. These updated European clinical guidelines represent the first comprehensive revision in over a decade for managing viral threats in one of medicine's most vulnerable populations.
The recommendations establish standardized protocols across eight major respiratory viruses affecting patients with leukemia, lymphoma, and bone marrow transplant recipients. For influenza, the guidelines endorse seasonal vaccines and early antiviral intervention while discouraging routine prophylactic antivirals in immunocompromised patients. Regarding RSV, newly licensed vaccines receive conditional support despite limited efficacy data in this population. The guidelines recommend passive immunization with monoclonal antibodies for children under two, but acknowledge insufficient evidence for broader prophylactic use.
These evidence-based protocols address a critical gap in specialized care. Blood cancer patients and transplant recipients experience prolonged viral shedding, higher complication rates, and increased mortality from respiratory infections that pose minimal risk to healthy adults. The guidelines' significance extends beyond immediate patient care—they establish research priorities for vaccine effectiveness studies and antiviral trials specifically in immunocompromised populations. While representing meaningful progress in standardizing care, the recommendations also highlight substantial knowledge gaps, particularly regarding optimal prophylaxis strategies and treatment protocols for adults with severe immunodeficiency. The document underscores how common respiratory viruses transform into life-threatening challenges when immune systems are compromised by cancer treatment.